JP2015532265A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015532265A5 JP2015532265A5 JP2015533277A JP2015533277A JP2015532265A5 JP 2015532265 A5 JP2015532265 A5 JP 2015532265A5 JP 2015533277 A JP2015533277 A JP 2015533277A JP 2015533277 A JP2015533277 A JP 2015533277A JP 2015532265 A5 JP2015532265 A5 JP 2015532265A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- adb
- composition
- fiber
- epithelial tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000835 fiber Substances 0.000 claims 45
- 108090000765 processed proteins & peptides Proteins 0.000 claims 37
- 229920001184 polypeptide Polymers 0.000 claims 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims 36
- 239000000203 mixture Substances 0.000 claims 33
- 210000000981 epithelium Anatomy 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 19
- 229940124597 therapeutic agent Drugs 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 208000035475 disorder Diseases 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 102000005707 Desmoglein 2 Human genes 0.000 claims 7
- 108010045583 Desmoglein 2 Proteins 0.000 claims 7
- 206010061968 Gastric neoplasm Diseases 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 210000001519 tissue Anatomy 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 206010006187 Breast cancer Diseases 0.000 claims 5
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 208000029742 colonic neoplasm Diseases 0.000 claims 5
- 229940127089 cytotoxic agent Drugs 0.000 claims 5
- 239000000032 diagnostic agent Substances 0.000 claims 5
- 239000012216 imaging agent Substances 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 4
- 229940039227 diagnostic agent Drugs 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000037841 lung tumor Diseases 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000013718 rectal benign neoplasm Diseases 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 3
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 3
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 3
- 206010029098 Neoplasm skin Diseases 0.000 claims 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000009956 adenocarcinoma Diseases 0.000 claims 3
- 229960005395 cetuximab Drugs 0.000 claims 3
- 201000011523 endocrine gland cancer Diseases 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 208000014018 liver neoplasm Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 208000025402 neoplasm of esophagus Diseases 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 208000023958 prostate neoplasm Diseases 0.000 claims 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 3
- 229960000575 trastuzumab Drugs 0.000 claims 3
- 208000025421 tumor of uterus Diseases 0.000 claims 3
- 206010046766 uterine cancer Diseases 0.000 claims 3
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 3
- 101150029707 ERBB2 gene Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 229940127121 immunoconjugate Drugs 0.000 claims 2
- 238000009169 immunotherapy Methods 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 230000002285 radioactive effect Effects 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023665 Barrett oesophagus Diseases 0.000 claims 1
- 208000017283 Bile Duct disease Diseases 0.000 claims 1
- 206010056375 Bile duct obstruction Diseases 0.000 claims 1
- 206010004637 Bile duct stone Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010007882 Cellulitis Diseases 0.000 claims 1
- 206010008635 Cholestasis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 208000016222 Pancreatic disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000000234 capsid Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 201000001883 cholelithiasis Diseases 0.000 claims 1
- 229950007276 conatumumab Drugs 0.000 claims 1
- 229960002806 daclizumab Drugs 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960001776 edrecolomab Drugs 0.000 claims 1
- 208000001130 gallstones Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 229950002884 lexatumumab Drugs 0.000 claims 1
- 229950002950 lintuzumab Drugs 0.000 claims 1
- 229960002450 ofatumumab Drugs 0.000 claims 1
- 208000024691 pancreas disease Diseases 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 229960005570 pemtumomab Drugs 0.000 claims 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 1
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 239000002525 vasculotropin inhibitor Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 210000002845 virion Anatomy 0.000 claims 1
- 229950009002 zanolimumab Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705523P | 2012-09-25 | 2012-09-25 | |
| US61/705,523 | 2012-09-25 | ||
| PCT/US2013/061431 WO2014052322A1 (en) | 2012-09-25 | 2013-09-24 | Desmoglein 2 (dsg2) binding proteins and uses therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015532265A JP2015532265A (ja) | 2015-11-09 |
| JP2015532265A5 true JP2015532265A5 (enExample) | 2016-10-20 |
| JP6290221B2 JP6290221B2 (ja) | 2018-03-07 |
Family
ID=49293927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015533277A Active JP6290221B2 (ja) | 2012-09-25 | 2013-09-24 | デスモグレイン２（ｄｓｇ２）結合タンパク質およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20150246949A1 (enExample) |
| EP (1) | EP2900818B1 (enExample) |
| JP (1) | JP6290221B2 (enExample) |
| KR (1) | KR102175034B1 (enExample) |
| CN (2) | CN109796524A (enExample) |
| AU (1) | AU2013323775B2 (enExample) |
| WO (1) | WO2014052322A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| WO2017147265A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| TWI791440B (zh) * | 2016-06-06 | 2023-02-11 | 艾斯克立必恩股份有限公司 | Dsg2-衍生肽 |
| JP6923957B2 (ja) | 2016-06-06 | 2021-08-25 | アスクリピウム タイワン シーオー．， エルティーディー．Ａｓｃｌｅｐｉｕｍｍ Ｔａｉｗａｎ Ｃｏ．， Ｌｔｄ． | Ｄｓｇ２モノクローナル抗体およびその応用 |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| US20200347101A1 (en) * | 2018-01-25 | 2020-11-05 | Pai Life Sciences, Inc. | Conjugatable desmoglein 2 (dsg2) binding proteins and uses therefor |
| BR112020019942A2 (pt) | 2018-04-09 | 2021-01-26 | Salk Institute For Biological Studies | composições de adenovírus oncolítico com propriedades de replicação aprimoradas |
| WO2021072112A1 (en) | 2019-10-09 | 2021-04-15 | Hdt Bio Corp. | Detection of desmoglein-2 in cancers of epithelial origin |
| CN111879940B (zh) * | 2020-04-28 | 2022-02-01 | 中国科学院微生物研究所 | 肺结核标志物及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| AU767975B2 (en) | 1998-09-11 | 2003-11-27 | Genvec, Inc. | Alternatively targeted adenovirus |
| CA2392272A1 (fr) | 1999-11-25 | 2001-05-31 | Transgene S.A. | Fibre adenovirable modifiee et utilisations |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| US6635466B2 (en) * | 2001-01-09 | 2003-10-21 | University Of Iowa Research Foundation | Adenovirus serotype 30 (Ad30) |
| EP1531757B1 (en) | 2002-07-19 | 2016-09-07 | Omeros Corporation | Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from |
| US20050181375A1 (en) * | 2003-01-10 | 2005-08-18 | Natasha Aziz | Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer |
| CN101068933A (zh) * | 2004-08-25 | 2007-11-07 | 细胞基因系统有限公司 | 用于肿瘤细胞增强转导的纤维修饰的腺病毒载体 |
| US8722853B2 (en) * | 2010-06-10 | 2014-05-13 | University Of Washington Through Its Center For Commercialization | Methods and systems for adenovirus interaction with desmoglein 2 (DSG2) |
-
2013
- 2013-09-24 US US14/429,705 patent/US20150246949A1/en not_active Abandoned
- 2013-09-24 EP EP13771350.9A patent/EP2900818B1/en active Active
- 2013-09-24 CN CN201811167962.0A patent/CN109796524A/zh active Pending
- 2013-09-24 AU AU2013323775A patent/AU2013323775B2/en active Active
- 2013-09-24 JP JP2015533277A patent/JP6290221B2/ja active Active
- 2013-09-24 WO PCT/US2013/061431 patent/WO2014052322A1/en not_active Ceased
- 2013-09-24 CN CN201380060698.XA patent/CN105008535B/zh active Active
- 2013-09-24 KR KR1020157010265A patent/KR102175034B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013538040A5 (enExample) | ||
| RU2016110826A (ru) | Белки, связывающие десмоглеин 2 (dsg2), и их применение | |
| O'Bryan et al. | Oncolytic virotherapy for breast cancer treatment | |
| US10919977B2 (en) | Bispecific tetravalent antibodies and methods of making and using thereof | |
| JP2020517635A5 (enExample) | ||
| JP2014527814A5 (enExample) | ||
| Jayawardena et al. | Virus–receptor interactions: structural insights for oncolytic virus development | |
| JP2021533161A5 (enExample) | ||
| JP2016518325A5 (enExample) | ||
| JP2020521478A5 (enExample) | ||
| Wood et al. | Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105 | |
| JP2022530404A5 (enExample) | ||
| JP2018512175A5 (enExample) | ||
| JP2015529641A5 (enExample) | ||
| JP2012525128A5 (enExample) | ||
| CN105007939B (zh) | 人抗vegfr-2/kdr抗体 | |
| JP2024521472A5 (enExample) | ||
| WO2013123861A1 (zh) | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 | |
| CN103965363A (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| JP2014500862A5 (enExample) | ||
| CN105008535A (zh) | 桥粒芯糖蛋白2(dsg2)结合蛋白质及其用途 | |
| WO2012102363A1 (ja) | 薬物送達システムおよびその利用 | |
| JP2022514354A5 (enExample) | ||
| WO2014166029A1 (zh) | 针对表皮生长因子受体的抗体 | |
| US20210277128A1 (en) | Bispecific Tetravalent Antibodies and Methods of Making and Using Thereof |